{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T12:18:08Z","timestamp":1791980288379,"version":"4.4.0"},"reference-count":20,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T00:00:00Z","timestamp":1729468800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>Asciminib, a novel allosteric BCR::ABL1 inhibitor, targets the ABL1 myristoyl pocket to potentially reduce toxicity and enhance efficacy. It is approved for Philadelphia chromosome\u2010positive chronic\u2010phase chronic myeloid leukemia (CML\u2010CP) in patients with resistance or intolerance to two or more tyrosine kinase inhibitors (TKIs) or those with the T315I mutation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This retrospective analysis evaluated patients with CML treated with asciminib under a managed\u2010access program across eight Israeli centers from July 2019 to August 2022. We assessed treatment responses, toxicities, event\u2010free survival (EFS), and overall survival (OS) using Kaplan\u2013Meier methods.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The study included 30 patients who had received a median of three prior TKIs, with 73% starting asciminib due to intolerance. After a median follow\u2010up of 7.1\u2009months, 85% of those without prior complete cytogenetic response (CCyR) achieved CCyR, and 60% previously not in major molecular response (MMR) attained MMR. Resistance was rare (10%), with no cardiovascular events reported despite high baseline comorbidity (73%). Median EFS was 47\u2009months; median OS was not reached.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Asciminib demonstrates significant efficacy and tolerability in heavily pretreated patients with CML\u2010CP, with no new cardiovascular events observed. Further long\u2010term studies are necessary to explore its full cardiovascular impact.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ejh.14330","type":"journal-article","created":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T01:39:24Z","timestamp":1729561164000},"page":"258-263","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Asciminib in Advanced\u2010Line Treatment of Chronic Myeloid Leukemia"],"prefix":"10.1111","volume":"114","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2035-2703","authenticated-orcid":false,"given":"Adi","family":"Shacham\u2010Abulafia","sequence":"first","affiliation":[{"name":"Davidoff Cancer Center, Rabin Medical Center Institute of Hematology  Petah\u2010Tikva Israel"},{"name":"School of Medicine, Faculty of Medicine and Health Sciences Tel Aviv University  Tel Aviv Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulia","family":"Volcheck","sequence":"additional","affiliation":[{"name":"Hematology Division Chaim Sheba Medical Center  Tel\u2010Hashomer Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Ellis","sequence":"additional","affiliation":[{"name":"School of Medicine, Faculty of Medicine and Health Sciences Tel Aviv University  Tel Aviv Israel"},{"name":"Meir Medical Center Hematology Institute  Kfar Saba Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirley","family":"Shapira","sequence":"additional","affiliation":[{"name":"School of Medicine, Faculty of Medicine and Health Sciences Tel Aviv University  Tel Aviv Israel"},{"name":"Meir Medical Center Hematology Institute  Kfar Saba Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigal","family":"Tavor","sequence":"additional","affiliation":[{"name":"Hemato\u2010Oncology Department Assuta Medical Center  Tel Aviv Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Gourevitch","sequence":"additional","affiliation":[{"name":"Hematology Institute Soroka University Medical Center  Beer\u2010Sheva Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Kreiniz","sequence":"additional","affiliation":[{"name":"The Division of Hematology Bnai Zion Medical Center  Haifa Israel"},{"name":"The Ruth and Bruce Rappaport Faculty of Medicine  Haifa Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anfisa","family":"Stanevski","sequence":"additional","affiliation":[{"name":"Davidoff Cancer Center, Rabin Medical Center Institute of Hematology  Petah\u2010Tikva Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pia","family":"Raanani","sequence":"additional","affiliation":[{"name":"Davidoff Cancer Center, Rabin Medical Center Institute of Hematology  Petah\u2010Tikva Israel"},{"name":"School of Medicine, Faculty of Medicine and Health Sciences Tel Aviv University  Tel Aviv Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"Koren\u2010 Michowitz","sequence":"additional","affiliation":[{"name":"School of Medicine, Faculty of Medicine and Health Sciences Tel Aviv University  Tel Aviv Israel"},{"name":"Shamir Medical Center Department of Hematology  Haifa Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,10,21]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.66.2866"},{"issue":"5","key":"e_1_2_8_3_1","article-title":"Chronic Myeloid Leukemia in 2020","volume":"4","author":"Hehlmann R.","year":"2020","journal-title":"Hema"},{"issue":"7","key":"e_1_2_8_4_1","first-page":"421","article-title":"The \u201cHit Hard and Hit Early\u201d Approach to the Treatment of Chronic Myeloid Leukemia: Implications of the Updated National Comprehensive Cancer Network Clinical Practice Guidelines for Routine Practice","volume":"11","author":"Akard L. P.","year":"2013","journal-title":"Clinical Advances in Hematology & Oncology"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00603"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ddtec.2014.03.003"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-09-594432"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2023.02.008"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2020.106458"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1902328"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009984"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-181937"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-022-04932-6"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2023.107374"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2400858"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0776-2"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00420-8"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-165501"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02278-8"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-023-01860-w"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023022538"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.14330","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T13:52:31Z","timestamp":1737467551000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.14330"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,21]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10.1111\/ejh.14330"],"URL":"https:\/\/doi.org\/10.1111\/ejh.14330","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,21]]},"assertion":[{"value":"2024-08-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}